AbbVie is a research-based biopharma company, developing small molecules and biologics for the treatment of various diseases.
In 2013, Abbott Laboratories splits into two entities- Abbott, Inc., to market medical and diagnostic products and AbbVie, Inc. the research and development focused biopharma company.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Veliparib / ABT 888 | PARP | III | Metastatic Breast Cancer | NCT02163694 | Small Molecule |
| III | Ovarian Cancer | NCT02470585 | |||
| III | Non-Small Cell Lung Cancer | NCT02106546 | |||
| Venclexta™ / Venetoclax / ABT 199 / GDC-0199 | Bcl-2 | III | Multiple Myeloma | NCT03539744 | Small Molecule |
| II | Waldenstrom Macroglobulinemia | NCT02677324 | |||
| Telisotuzumab vedotin / ABBV-399 | cMet | II | Non Small Cell Lung Cancer | NCT03539536 | Antibody Drug Conjugate |
| I | Advanced Solid Tumors Cancer | NCT03311477 | |||
| Mirzotamab / clezutoclax / ABBV-155 | CD275 | I | Advanced Solid Tumors | NCT03595059 | Antibody Drug Conjugate |
| ABBV-621 | TRAIL | I | Advanced Solid Tumors Cancer | NCT03082209 | Fusion Protein |
| Hematologic Malignancies | |||||
| CCW702 | CD3-PSMA | I | Prostatic Cancer (mCRPC) | NCT04077021 | Bispecific Antibody |
| CLBR001 + SWI019 * | CD19 | I | R/R B-cell Lymphomas | NCT04450069 | CAR-T + |
| Diffuse Large B Cell Lymphoma | Monoclonal Antibody | ||||
| ABBV-011 | Undisclosed | I | R/R Small Cell Lung Cancer | NCT03639194 | Antibody Drug Conjugate |
| ABBV-151 | GARP- TGF-β1 | I | Advanced Solid Tumors Cancer | NCT03821935 | Monoclonal Antibody |
| ABBV-155 | Undisclosed | I | Small cell lung cancer | NCT03595059 | Antibody Drug Conjugate |
| Non-Small cell lung cancer | |||||
| Budigalimab /ABBV-181 | PD-1 | I | Advanced Solid Tumors | NCT03000257 | Monoclonal Antibody |
| ABBV-184 | Survivin, CD3 | I | Acute Myeloid Leukemia (AML) | NCT04272203 | Bispecific Antibody |
| Non Small Cell Lung Cancer | |||||
| ABBV-368 | OX40 | I | Advanced Solid Tumors | NCT03071757 | Monoclonal Antibody |
| ABBV-467 | MCL1 | I | R/R Multiple Myeloma | NCT04178902 | Small Molecule |
| ABBV-621 | TRAIL-R1 | I | Advanced Solid Tumors | NCT03082209 | Fusion Protein |
| Hematologic Malignancies | |||||
| Cofetuzumab Pelidotin/ ABBV-647 | PTK7 | I | Non-Small Cell Lung Cancer | NCT04189614 | Antibody Drug Conjugate |
| ABBV-744 | BET | I | Acute Myeloid Leukemia | NCT03360006 | Small Molecule |
| ABBV-927 | CD40 | I | Advanced Solid Tumors | NCT02988960 | Monoclonal Antibody |
AbbVie Active Oncology Pipeline Drug Description
- Veliparib (ABT-888) is a PARP inhibitor being investigated to treat non-small cell lung cancer, BRCA breast cancer and ovarian cancer.
- Mirzotamab clezutoclax / ABBV-155 is an antibody-drug conjugate or ADC targeting CD275.
- ABBV-621 is a first-in-class, second-generation TRAIL-receptor agonist under development for the treatment of solid and hematologic tumors.
- CCW702 is a bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities.
- CCW702 is an investigational immunotherapy for metastatic castration resistant prostate cancer being developed by Calibr in a first-in-patient clinical trial. AbbVie holds an option to license the program at the conclusion of the trial.
- CLBR001 + SWI019 is a two-component therapy comprising an autologous chimeric antigen receptor T (CAR-T) cell product (CLBR001, the switchable CAR-T cell (sCAR-T)) and an anti-CD19 (cluster of differentiation antigen 19) antibody (SWI019, the switch, a biologic). In combination, SWI019 acts as an adapter molecule that controls the activity of the CLBR001 CAR-T cell product.
- AbbVie and Calibr are working together to develop novel switchable T-cell therapies directed to various tumor targets identified by AbbVie.
- ABBV-011 is a targeted ADC composed of a monoclonal antibody directed against an as of yet undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, with potential antineoplastic activity; being investigated to treat small cell lung cancer.
- ABBV 151 (previously ARGX 115), a first-in-class antibody against the LRRC32/GARP (glycoprotein A repetitions predominant) protein, GARP-TGFβ1 complex and blocks TGFβ1 release.
- ABBV-181 is an anti-PD1 monoclonal antibody that is being developed for combinations with other AbbVie molecules for solid tumors and hematologic malignancies.
- ABBV-184 is a is a bispecific T cell engager ( BiTE ) antibody that targets survivin; being investigated for the treatment of AML and NSCLC.
- ABBV-368 is an agonistic anti-OX40 monoclonal antibody that is being investigated in a Phase 1 clinical trial for solid tumors.
- ABBV-467 is an MCL1 Inhibitor being investigated for the treatment of hematological cancer.
- ABBV-621 is a a first-in-class, second-generation, potent tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist fusion protein that induces apoptotic cell death, particularly in DR4/5 expressing tumor models.
- ABBV-647 is an targeted antibody drug conjugate inhibitor of PTK7 being investigated for the treatment of solid tumors.
- ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.
- ABBV-927 is an agonistic anti-CD40 monoclonal antibody that is being investigated in a Phase 1 clinical trial for solid tumors.
Page 2 of 2
